EyeGate Completes Enrollment, Receives Milestone Payment for Phase III Study of EGP-437 in Anterior Uveitis

April 13, 2018: By Jon Swedien

EyeGate Pharmaceuticals has completed enrollment in a pivotal Phase III study of EGP-437 for noninfectious anterior uveitis, the Waltham, Massachusetts, company announced April 6.

The completion of patient enrollment triggered a milestone payment in an exclusive, worldwide licensing deal for EGP-437 that EyeGate signed with Bausch + Lomb in 2015.

EyeGate expects top line data in Q3-2018. If the trial results are positive, EyeGate plans to submit a new drug application to the FDA in the first half of 2019, said President and CEO Stephen From.

The double-masked, randomized, positive-controlled trial enrolled 250 patients in the US. It was designed to assess the safety and efficacy of iontophoretically delivered EGP-437 in patients with unilateral or bilateral noninfectious anterior segment uveitis.

The primary efficacy endpoint is the proportion of subjects with an anterior chamber cell count of zero at day 14.

Subjects were provided three treatments of either EGP-437 iontophoresis treatment or a placebo iontophoresis treatment. Patients enrolled in the EGP-437 arm were provided placebo eye drops, while patients receiving placebo iontophoresis treatment were given prednisolone acetate (1%) drops. Eye drops for both arms were administered for a period of up to 28 days and for up to eight drops per day.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US Health Secretary Alex Azar Takes Aim at Rebates in US Senate Hearing

Beyeonics Surgical Raises $11.5 Million in Initial Funding Round

MeiraGTx Raises $75 Million in Initial Public Offering

GenSight to Pursue Approval for LHON Gene Therapy Candidate, Despite Phase III Setback

Optovue Receives FDA Clearance for AngioAnalytics, First OCT Angiography Metrics

Nexy Robotic Retinal Imaging System Receives FDA Clearance

Ocutrx Receives US Patent for Oculenz AR Glasses for Macular Degeneration

Allergan’s Bimatoprost SR Demonstrates Noninferiority to Timolol in Phase III Glaucoma Study

KKR to acquire Envision Healthcare, Including Amsurg ASC Business

Ophthalmologist Carmen Puliafito, MD, Seeks to Regain Medical License

Avedro Gains J Code for Photrexa Formulations in Preliminary CMS Decision

EyeGate Seeks to Study Ocular Bandage Gel in Punctate Epitheliopathy

Nicox, Ironwood to Collaborate on Novel Ophthalmic Treatments

US FDA Approves MDGH’s Moxidectin for Treatment of River Blindness

Bausch + Lomb Enrolls First Patient in Trial for enVista MX60EF Trifocal IOL

Cincinnati Eye Institute Partners with Private Equity Firm to Pursue National Expansion

Ophthotech Enters Gene Therapy Deals with University of Florida, University of Pennsylvania

Teva’s Launches Generic Version of Restasis in Canada

Clearside’s Phase II Trial for DME Candidate Meets Primary Endpoint

Orasis Raises $13 Million in Series B Financing

Coming soon

2018 Glaucoma Device Report: A Global Market Analysis for 2017 to 2023